cobalt (cas 10198-40-0) cardiomyopathy in hip arthroplasty

Add time:07/23/2019    Source:sciencedirect.com

Backgroundcobalt (cas 10198-40-0) toxicity-related cardiomyopathy in hip arthroplasty has recently been reported in the literature. The purpose of this review is to identify and assess available published evidence of cardiomyopathy in hip arthroplasty patients and to derive recommendations for management.

We also recommend Trading Suppliers and Manufacturers of cobalt (cas 10198-40-0). Pls Click Website Link as below: cas 10198-40-0 suppliers

Prev:Chemical modification with phthalic anhydride and chitosan: Viable options for the stabilization of raw starch digesting amylase from Aspergillus carbonarius
Next:3,3′-Bipyridazine: the ‘second-best’ bidiazine ligand for M(CO)4 fragments (M = Cr, Mo, W))